Innovent Licenses Anti-CD40L Antibody IBI355 to Spero for $1.1B Deal
Event summary
- Spero gains exclusive global rights (excluding Greater China) to IBI355, a Phase 2-ready anti-CD40L antibody, for upfront and potential $1.1B in milestones.
- Innovent retains China rights; plans Phase 2 trial for Sjögren's disease by early 2027.
- Spero targets IgG4-related disease (IgG4-RD) Phase 2 trial launch in Q2 2027.
- IBI355 is a third-generation Fc-silent antibody designed to avoid platelet activation issues of earlier CD40L inhibitors.
The big picture
This deal marks Spero's pivot into immunology, leveraging a clinically validated pathway with potential across multiple autoimmune conditions. For Innovent, it represents another high-value out-licensing agreement in its strategy to monetize R&D while retaining China rights. The $1.1B milestone structure underscores the high stakes in developing non-depleting therapies for chronic inflammatory diseases.
What we're watching
- Clinical Progress
- Whether IBI355 can demonstrate efficacy in IgG4-RD and Sjögren's disease, validating the CD40L pathway for broader autoimmune applications.
- Commercialization Strategy
- How Spero plans to position IBI355 against existing therapies in underserved autoimmune indications.
- Pipeline Expansion
- The pace at which Innovent and Spero advance additional immune-mediated disease targets using the CD40L platform.